Trial Profile

A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza A vaccine H5N1-Baxter (Primary)
Indications Influenza A virus H5N1 subtype
Focus Adverse reactions; Pharmacodynamics
Sponsors Baxter Healthcare Corporation; Ology Bioservices

Most Recent Events

16 Sep 2013 Results published in the Journal of Infectious Diseases.
28 Sep 2012 Planned end date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
07 Jul 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com